clinical trial · NCT05573698
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
Friedreich AtaxiaDT-216Placebo
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of multiple doses of intravenous DT-216 in adult patients with Friedrich Ataxia.
started
Sep 27, 2022
primary completion
Aug 25, 2023
completion
Aug 25, 2023
last updated
Feb 29, 2024
official title
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose and Multi-Dose Study of DT-216 in Adult Patients With Friedreich Ataxia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol